Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › dapagliflozin

dapagliflozin

22 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of dapagliflozin

89 trials tracked of dapagliflozin: 69 in phase 3 or 4 and 30 with published results. The most-cited published study has 645 citations.

89Trials tracked
69Phase 3 & 4
0Recruiting
30With published results
Phase distribution
Phase 4 23 Phase 3 46 Phase 2 13 Phase 1 4 Other / NA 3
  1. Phase 3 Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment Completed · 645 cited
  2. Phase 4 Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure Completed · 425 cited
  3. Phase 3 Add-on to Thiazolidinedione (TZD) Failures Completed · 402 cited
  4. Phase 3 Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo Completed · 389 cited
  5. Phase 3 A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes Completed · 361 cited
  6. Phase 3 An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets Completed · 313 cited
Show 44 more trials
  1. Phase 3 Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack. Completed · 267 cited
  2. Phase 4 Effects of Dapagliflozin 10 mg on Insulin Resistance in Patients With Type 2 Diabetes Mellitus Completed · 246 cited
  3. Phase 4 An Investigation Into The Anti-hypertensive And Potential Anti-inflammatory Actions Of Dapagliflozin Completed · 189 cited
  4. Phase 3 Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes Completed · 149 cited
  5. Phase 3 Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes Completed · 85 cited
  6. Phase 3 Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years Completed · 84 cited
  7. Phase 3 Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes Completed · 77 cited
  8. Phase 3 Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes Completed · 77 cited
  9. Phase 4 Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea Completed · 73 cited
  10. Phase 3 Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes Completed · 69 cited
  11. Phase 4 Effects of 5 Weeks Treatment With Dapagliflozin in Type 2 Diabetes Patients on How the Hormone Insulin Acts on Sugar Uptake in Muscles. Completed · 59 cited
  12. Phase 3 A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838) Completed · 56 cited
  13. Phase 3 DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction Completed · 53 cited
  14. Phase 3 DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction Completed · 53 cited
  15. Phase 4 Effects of SGLT-2 Inhibition on Myocardial Fibrosis and Inflammation as Assessed by Cardiac MRI in Patients With DM2 Completed · 42 cited
  16. Phase 3 SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2 Completed · 34 cited
  17. Phase 3 Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old Completed · 34 cited
  18. Phase 3 Phase III Insulin Add-On Asia Regional Program - ST Completed · 26 cited
  19. Phase 3 Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure Completed · 25 cited
  20. Phase 4 Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D) Completed · 15 cited
  21. Phase 3 A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone Completed · 13 cited
  22. Phase 3 Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure. Completed · 13 cited
  23. Phase 4 Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria Completed · 10 cited
  24. Phase 3 A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease Completed · 6 cited
  25. Phase 4 Vildagliptin Versus Dapagliflozin on Glucagon Completed
  26. Phase 4 Foxiga Korea Local Phase 4 Study Completed
  27. Phase 4 A Clinical Study to Investigate the Effects of Dapagliflozin on Heart Work, Heart Nutrient Uptake, and Heart Muscle Efficiency in Type 2 Diabetes Patients Completed
  28. Phase 4 Dapagliflozin and Cholesterol Metabolism in Type 2 Diabetes (DM2) Completed
  29. Phase 4 Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes Completed
  30. Phase 4 Effect of Dapagliflozin on Blood Pressure Variability in Prediabetes and Prehypertension Completed
  31. Phase 4 Dapagliflozin Effects on Epicardial Fat Completed
  32. Phase 4 Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes Completed
  33. Phase 4 Dapagliflozin at Discharge on Hospital Heart Failure Readmission Completed
  34. Phase 4 Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects Completed
  35. Phase 4 Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM Completed
  36. Phase 4 Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration Completed
  37. Phase 4 Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation Completed
  38. Phase 4 Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients Completed
  39. Phase 4 Anti-Diabetic Medications to Fight PD and LBD Completed
  40. Phase 3 A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise Completed
  41. Phase 3 A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone Completed
  42. Phase 3 Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone Completed
  43. Phase 3 A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes Completed
  44. Phase 3 Paradoxical Stimulation of Hepatic Glucose Production With Dapagliflozin Completed

Showing the 50 most-cited and recently-updated of 89 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
SGLT2 inhibitors provide robust prognostic benefits in heart failure with inconsistent results in post-myocardial infarction settings
Cardiology Sys. Review
SGLT2 inhibitors provide robust prognostic benefits in heart failure with inconsistent results in post-myocardial infarction settings SGLT2 inhibitors show promise for heart failure and diabetes
This narrative review examines the cardiovascular and metabolic effects of SGLT2 inhibitors, specifically empagliflozin and dapagliflozin. T…
New evidence shows how SGLT2 inhibitors may protect the heart and manage risks for patients with type 2 diabetes and heart failure.
Frontiers Jun 9, 2026
Network meta-analysis compares bexagliflozin efficacy and safety with other SGLT2 inhibitors in type 2 diabetes
Diabetes & Endocrinology Meta-analysis
Network meta-analysis compares bexagliflozin efficacy and safety with other SGLT2 inhibitors in type 2 diabetes New analysis shows bexagliflozin helps lower blood sugar and weight in adults with type 2 diabetes compared to other drugs
This systematic review and network meta-analysis synthesized evidence on bexagliflozin versus other SGLT2 inhibitors and placebo in adults w…
A large review of 26,838 patients found bexagliflozin lowers blood sugar and weight well. It also lowers blood pressure and causes fewer inf…
Frontiers May 13, 2026
SGLT-2 inhibitors reduce heart failure hospitalization and stroke in patients with acute coronary syndrome
Cardiology Meta-analysis
SGLT-2 inhibitors reduce heart failure hospitalization and stroke in patients with acute coronary syndrome SGLT-2 Drugs Cut Stroke Risk After Heart Attack
This meta-analysis evaluated SGLT-2 inhibitors in patients hospitalized for acute coronary syndrome with additional risk factors. The analys…
New research shows that a specific diabetes drug can lower the risk of stroke and heart failure in people recovering from a heart attack.
May 8, 2026
Network meta-analysis compares glucose-lowering therapies for heart failure with reduced ejection fraction and type 2 diabetes
Cardiology Meta-analysis
Network meta-analysis compares glucose-lowering therapies for heart failure with reduced ejection fraction and type 2 diabetes Sotagliflozin Cuts Heart Failure Risk By Half In High-Risk Patients
This systematic review and network meta-analysis synthesized evidence on three glucose-lowering therapies for patients with coexisting heart…
New drugs for diabetes could also save lives in people with heart failure and lower the need for hospital visits.
Frontiers May 8, 2026
Zibotentan plus dapagliflozin shows no HVPG reduction in compensated cirrhosis
Gastroenterology RCT
Zibotentan plus dapagliflozin shows no HVPG reduction in compensated cirrhosis Early trial shows zibotentan plus dapagliflozin trended toward lowering blood pressure in cirrhosis patients
This Phase II randomized placebo-controlled exploratory study in 28 patients with compensated cirrhosis found that zibotentan 2.5 mg plus da…
An early study found that a combination drug lowered blood pressure in patients with compensated cirrhosis, though it did not conclusively i…
May 1, 2026
Non-randomized preprint on dapagliflozin and epicardial adipose tissue in HFpEF
Cardiology
Non-randomized preprint on dapagliflozin and epicardial adipose tissue in HFpEF Dapagliflozin linked to fat loss in heart failure patients
This preprint reports a non-randomized clinical trial in 60 patients with left ventricular diastolic dysfunction.
Adding dapagliflozin to standard care reduced epicardial fat in a small group of heart failure patients, though this preprint study needs co…
Apr 28, 2026
Meta-analysis of dapagliflozin for renal outcomes in type 2 diabetes and CKD
Diabetes & Endocrinology Meta-analysis
Meta-analysis of dapagliflozin for renal outcomes in type 2 diabetes and CKD SGLT2 inhibitors lower kidney failure risk in type 2 diabetes patients
This systematic review and meta-analysis of 10 studies synthesized evidence on dapagliflozin for renal outcomes in patients with type 2 diab…
A review of ten studies shows these drugs reduce kidney failure risk in people with type 2 diabetes and kidney disease.
Frontiers Apr 24, 2026
Systematic review and meta-analysis shows dapagliflozin increases hemoglobin in chronic kidney disease patients
Nephrology Meta-analysis
Systematic review and meta-analysis shows dapagliflozin increases hemoglobin in chronic kidney disease patients Common Diabetes Drug May Help Anemia in Kidney Disease
This systematic review and meta-analysis evaluated dapagliflozin in chronic kidney disease (CKD) patients with anemia.
This study suggests a common diabetes drug could treat anemia in kidney patients without the risks of current options.
Apr 24, 2026
Combination valsartan and dapagliflozin improves blood pressure and glucose in Type 2 Diabetes and hypertension
Diabetes & Endocrinology Cohort
Combination valsartan and dapagliflozin improves blood pressure and glucose in Type 2 Diabetes and hypertension Two Common Heart and Kidney Drugs Work Better Together Than Alone
This retrospective cohort study of 245 patients with coexisting Type 2 Diabetes Mellitus and hypertension found that combination therapy wit…
For patients with diabetes and high blood pressure, combining two common medications may offer stronger protection for the heart and kidneys…
Frontiers Apr 24, 2026
Network meta-analysis of novel antidiabetic drugs in T2DM with CKD shows sotagliflozin, empagliflozin, and semaglutide rank highest for cardiovascular and renal outcomes
Diabetes & Endocrinology Meta-analysis
Network meta-analysis of novel antidiabetic drugs in T2DM with CKD shows sotagliflozin, empagliflozin, and semaglutide rank highest for cardiovascular and renal outcomes A Clear Winner Emerges for Diabetes Patients with Kidney Disease
This network meta-analysis evaluated novel antidiabetic drugs, including SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors, i…
For millions managing both diabetes and kidney disease, new research clarifies which medications offer the best protection for their heart a…
Frontiers Apr 12, 2026
FDA Approves Dapagliflozin Tablets (dapagliflozin) for Heart Failure Risk Reduction and Glycemic Control in Type 2 Diabetes
Diabetes & Endocrinology FDA Approval
FDA Approves Dapagliflozin Tablets (dapagliflozin) for Heart Failure Risk Reduction and Glycemic Control in Type 2 Diabetes FDA approves a diabetes drug that also helps protect the heart in certain adults
The FDA has approved dapagliflozin tablets to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and establ…
A new diabetes tablet now helps control blood sugar while also lowering the risk of heart failure hospitalization for adults with heart dise…
FDA Apr 10, 2026
FDA Approves Dapagliflozin Tablets (dapagliflozin) for Type 2 Diabetes and Heart Failure Risk Reduction
Diabetes & Endocrinology FDA Approval
FDA Approves Dapagliflozin Tablets (dapagliflozin) for Type 2 Diabetes and Heart Failure Risk Reduction FDA approves a new pill for type 2 diabetes that also helps protect the heart
The FDA has approved dapagliflozin tablets for two indications in adults with type 2 diabetes mellitus: to improve glycemic control and to r…
A new FDA-approved pill for type 2 diabetes now helps lower blood sugar while also reducing the risk of hospitalization for heart failure.
FDA Apr 10, 2026

All dapagliflozin Articles